KENDAL NOBLE: Open Payments
NPI 1558831644 · STAR CITY, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$935 in 44 payments from 12 companies in 2025. Trend: 2023 $636 · 2024 $888 · 2025 $935
Food & beverage: $935
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $379 |
| Novo Nordisk Inc | 2 | $112 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $98 |
| AstraZeneca Pharmaceuticals LP | 4 | $72 |
| Lundbeck LLC | 4 | $59 |
| Axsome Therapeutics, Inc. | 3 | $53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $35 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| PFIZER INC. | 2 | $32 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $31 |
Products named: VRAYLAR, QULIPTA, Ozempic, CAPLYTA, REXULTI, FARXIGA, Auvelity, JARDIANCE.
Industry payments across AR — which companies pay providers there.
